Cadila Healthcare shares jump 1.5%
Shares of Cadila Healthcare gained as much as 1.5% in Friday's trade as Zydus Cadila has received final approval from the US health regulator to market minocycline hydrochloride extended release...24-11-2017
24-11-2017
Press Release / Media Release
Zydus receives approval from the USFDA for Minocycline Hydrochloride Extended - Release Tablets24-11-2017
Zydus Cadila gets USFDA nod to sell erectile dysfunction drug
Zydus Cadila has received approval for the US health regulator to market Tadalafil tablets used for the treatment of erectile dysfunction in the American market. The company has received tentative...23-11-2017
Press Release / Media Release
Zydus receives tentative approval from the USFDA for Tadalafil Tablets USP23-11-2017
Press Release / Media Release
Zydus' oral anemia developmental candidate, ZYAN1 named as Desidustat by WHO20-11-2017
Zydus Cadila gets USFDA nod for drug used to reduce swelling
Zydus Cadila has received final approval from the US health regulator to market Ethacrynate sodium for injection, used to reduce swelling caused by various diseases. The company has received final...18-11-2017
Press Release / Media Release
Zydus receives final approval from the USFDA for Ethacrynate Sodium for Injection USP18-11-2017
Investor Presentation
Please find attached the investor presentation to be made to the select investors today i.e. November 15, 2017.15-11-2017
Cadila Healthcare's Q2 net up 33% to Rs 503 cr
Cadila Healthcare Limited, also known as Zydus Cadila, reported a net profit growth of 33 per cent at Rs 503 crore in second quarter ended September 30, 2017, up from roughly Rs 378 crore for the said period last year.While total income from operations grew by 35 per cent year-on-year in Q2 to stand at Rs 3234 crore, Cadila Healthcare's business in the US posted sales of Rs 1,644 crore, up by 66 per cent, the company stated in an official communique.During the quarter, the company launched four new products in the US including Mesalamine Delayed Release 1.2 g tablets (generic version of Lialda ) with a 180 days exclusivity and received approval for 32 new products, including the generic version of Asacol HD (Mesalamine DR 800 mg tablets) and the generic version of Tamiflu suspension (Oseltamivir Powder for Oral Suspension 6 mg/ ml). The company filed nine additional ANDAs with the USFDA in the second quarter this fiscal.As against US operations, Cadila Healthcare saw its India...14-11-2017